Glucose-responsive insulin is one of the technologies on the horizon that Kowalski says he’s most excited about. The oth…

Glucose-responsive insulin is one of the technologies on the horizon that Kowalski says he’s most excited about. The oth…
“This approach has the potential to provide diabetics with a new pancreas that is protected from the immune system, whic…
“In alignment with the ADA’s position that diabetes does not define people, the word ‘diabetic’ will no longer be used w…
Researchers have gained an understanding of these presymptomatic stages of type 1 diabetes through the TrialNet data, an…
Philip J. Shaw of the JDCA argues that their analysis of JDRF funding shows that not only has the amount of money being …
This is an important study because really it’s the first to show a defined effect between the development of the microbi…
The study could have important implications for identifying the disease at a very early stage, delaying its onset or eve…
Todd Hobbs, the chief medical officer for North America at Novo Nordisk, knows diabetes from all angles: as a patient; a…
Both type 1 and type 2 are on the rise: since 1985 the number of people with diabetes worldwide has increased ten-fold, …
I watched a controversial video documentary on The New York Times’s web site, Midnight Three & Six, about a family pumme…